<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21842" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Flumazenil</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharbaf Shoar</surname>
            <given-names>Nazila</given-names>
          </name>
          <aff>Ross University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bistas</surname>
            <given-names>Karlyle G.</given-names>
          </name>
          <aff>Medical University of the Americas</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nazila Sharbaf Shoar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karlyle Bistas declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21842.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Flumazenil is a benzodiazepine antagonist typically used&#x000a0;in overdose emergencies. The primary FDA-approved clinical uses for flumazenil include reversal agents for benzodiazepine overdose and postoperative sedation from benzodiazepine anesthetics. Flumazenil injection is indicated for a complete or partial reversal of the sedative effects of benzodiazepines in conscious sedation and general anesthesia in adult and pediatric populations. This activity&#x000a0;focuses on&#x000a0;the indications, mechanism of action, dosing, significant adverse effects, contraindications, monitoring, and toxicity of flumazenil so clinicians can direct patient therapy for&#x000a0;optimal outcomes in benzodiazepine reversal.&#x000a0;Empowering&#x000a0;clinicians with the necessary knowledge and skills to navigate flumazenil therapy is paramount.</p>
        <p>This&#x000a0;activity aims to empower healthcare professionals by clarifying their roles and fostering collaboration. Through a scientific understanding of flumazenil's pharmacology,&#x000a0;prescribing clinicians can tailor treatment plans to individual patient needs, ensuring safe and effective reversal of benzodiazepine-induced sedation.&#x000a0;Such a comprehensive approach minimizes the risk of adverse reactions and enhances overall care standards in treating benzodiazepine overdose.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patient encounters&#x000a0;necessitating flumazenil administration for benzodiazepine overdose reversal.</p></list-item><list-item><p>Differentiate between the FDA-approved and off-label indications for using flumazenil as an antidote.</p></list-item><list-item><p>Evaluate patients for potential withdrawal symptoms and adverse effects post-flumazenil administration.</p></list-item><list-item><p>Implement effective collaboration among interprofessional team members to improve treatment efficacy for patients who might benefit from flumazenil.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21842&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21842">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21842.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Flumazenil is a benzodiazepine antagonist.<xref ref-type="bibr" rid="article-21842.r1">[1]</xref><xref ref-type="bibr" rid="article-21842.r2">[2]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of benzodiazepine overdose</p>
          </list-item>
        </list>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; -Adult, Category B, Class IIa&#x000a0;&#x000a0;</p>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; -Pediatric, Category C, Class IIb&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Reversal of postoperative sedation from benzodiazepine anesthetics</p>
          </list-item>
        </list>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; -Adult, Category B, Class IIa</p>
        <p>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; -Pediatric, Category B, Class IIa</p>
        <list list-type="bullet">
          <list-item>
            <p>Flumazenil is indicated for a complete or partial reversal of the sedative effects of benzodiazepines in conscious sedation and general anesthesia in the adult and pediatric populations. In addition, flumazenil speeds the recovery from sedation following minor surgical procedures and shortens the post-operation monitoring period for minor surgery, resulting in earlier patient discharge.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Flumazenil is also indicated for managing and treating benzodiazepine overdose in adults. It is useful in reversing coma due to benzodiazepine overdose. Flumazenil is more effective in reversing sedation or coma in benzodiazepine intoxication than in patients with multiple drug overdoses.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>According to&#x000a0;the American Society of Anesthesiologists Task Force's guidelines for moderate procedural sedation and analgesia, flumazenil is useful for the reversal of benzodiazepine-induced sedation and respiratory depression.<xref ref-type="bibr" rid="article-21842.r3">[3]</xref>&#x000a0;The combination of remimazolam and flumazenil accelerates recovery from general anesthesia and reduces the risk of respiratory depression compared to propofol.<xref ref-type="bibr" rid="article-21842.r4">[4]</xref><xref ref-type="bibr" rid="article-21842.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label&#x000a0;Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alcohol withdrawal syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Baclofen reversal</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic recurring stupor</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cannabis toxicity</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hepatic encephalopathy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Benzodiazepines detoxification</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As the FDA has not approved flumazenil, the advantages and disadvantages of using this drug in non-FDA-approved conditions are based on the patient's condition and the clinician's&#x000a0;judgment.<xref ref-type="bibr" rid="article-21842.r6">[6]</xref><xref ref-type="bibr" rid="article-21842.r7">[7]</xref><xref ref-type="bibr" rid="article-21842.r8">[8]</xref><xref ref-type="bibr" rid="article-21842.r9">[9]</xref><xref ref-type="bibr" rid="article-21842.r10">[10]</xref><xref ref-type="bibr" rid="article-21842.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21842.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Flumazenil is a benzodiazepine antagonist. It competitively inhibits the activity of benzodiazepine and non-benzodiazepine substances that interact with benzodiazepine receptors site on the GABA/benzodiazepine receptor complex. It can also reverse the binding of benzodiazepines to benzodiazepine receptors.<xref ref-type="bibr" rid="article-21842.r12">[12]</xref>&#x000a0;Intravenous (IV) flumazenil&#x000a0;antagonizes&#x000a0;sedative effects, impairment of recall, and psychomotor impairment produced by benzodiazepines.<xref ref-type="bibr" rid="article-21842.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> After parenteral administration, the&#x000a0;onset of action is&#x000a0;approximately 1 to 2 minutes; 80% of response occurs within the&#x000a0;initial 3 minutes. The peak effect is observed 6 to 10 minutes after administration.&#x000a0;The duration of flumazenil ranges from 19 to 50 minutes, depending on the dose and plasma concentrations of benzodiazepines.</p>
        <p><bold>Distribution:</bold>&#x000a0;Flumazenil demonstrates extensive distribution in the extracellular space. The initial apparent volume of distribution is 0.5 L/kg, and steady-state plasma concentration is&#x000a0;0.9 to 1.1 L/kg. Plasma protein binding is approximately 50%. Albumin contributes to two-thirds of plasma protein binding.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Flumazenil undergoes near-complete metabolism, with minor fractions (&#x0003c;1%) excreted unchanged in urine. Key urine metabolites include the de-ethylated free acid and its glucuronide conjugate, without evident pharmacological activity based on preclinical studies. While several radioactive metabolites are produced, only the unchanged drug can cross the blood-brain barrier.<xref ref-type="bibr" rid="article-21842.r14">[14]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Radiolabeled flumazenil elimination concludes within 72 hours, with 90% to 95% radioactivity excreted in urine and 5% to 10% in feces. Flumazenil clearance primarily relies on hepatic metabolism. In healthy volunteers' studies, total clearance ranges from 0.8 to 1.0 L/hr/kg. The elimination half-life is about 54 minutes, varying by 21% (41 to 79 minutes). Therefore, re-sedation may occur within 1 to 2 hours after administration, requiring&#x000a0;additional&#x000a0;doses.<xref ref-type="bibr" rid="article-21842.r15">[15]</xref></p>
      </sec>
      <sec id="article-21842.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Flumazenil is for IV infusion. The injectable solution contains a concentration of 0.1 mg/mL of flumazenil. The solution is stable for 24 hours if drawn into a syringe or mixed with D5W, LR, or NS. The administration is&#x000a0;completed by freely running IV infusion into a large vein or a series of small injections.<xref ref-type="bibr" rid="article-21842.r16">[16]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>FDA Dosage for management of benzodiazepine overdose</p>
        <list list-type="bullet">
          <list-item>
            <p>The clinician should give the initial dosage of 0.2 mg IV for 30 seconds&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If the desired level of consciousness is not obtained after 30 seconds, the clinician can provide an additional dose of 0.3 mg IV over 30 seconds</p>
          </list-item>
          <list-item>
            <p>Repeat doses of 0.5 mg IV over 30 seconds at 1-minute intervals to a maximum cumulative dose of 3 mg is possible.</p>
          </list-item>
          <list-item>
            <p>Patients with partial response to 3 mg may require additional slow titration up to a total&#x000a0;dosage of 5 mg. If no response occurs after administration of 5 mg, the primary cause of sedation is not benzodiazepine-related, and further treatment with flumazenil&#x000a0;is ineffective.</p>
          </list-item>
          <list-item>
            <p>In reoccurrence, sedations repeat doses may be given at 20-minute intervals, not to exceed 1 mg (0.5 mg/minute) per dose or 3 mg/hour.</p>
          </list-item>
        </list>
        <p>FDA dosage for benzodiazepine reversal when used in conscious sedation or general anesthesia</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial dosage of 0.2 mg IV over 15 seconds&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If the desired level of consciousness is not obtained after 45 seconds, 0.2 mg IV may be repeated at 1-minute intervals. A maximum of&#x000a0;4 additional doses may be given if required.</p>
          </list-item>
          <list-item>
            <p>The maximum total cumulative dose of 1 mg</p>
          </list-item>
          <list-item>
            <p>In the reoccurrence of sedation, repeat doses may be given at 20-minute intervals, not to exceed 0.2 mg/min per dose or 3 mg/hour total.</p>
          </list-item>
        </list>
        <p>The American Association for the Study of Liver Diseases states&#x000a0;that flumazenil only produces transient improvement in overt hepatic encephalopathy without long-term survival benefits.<xref ref-type="bibr" rid="article-21842.r17">[17]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>Hepatic dosing is necessary for patients with hepatic insufficiency. The initial dose of flumazenil for benzodiazepine reversal remains the same, but subsequent doses should be decreased in&#x000a0;dosage&#x000a0;or frequency.<xref ref-type="bibr" rid="article-21842.r18">[18]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;FDA-approved product labeling specifies that in cases of renal failure (creatinine clearance &#x0003c;10 mL/min) and during hemodialysis, the pharmacokinetics of flumazenil remain unaffected.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>A study investigated cases of poisoning in pregnant individuals using data from the Toxicology Investigators Consortium Registry's 37 sites from January 2010 to December 2012. The results revealed that flumazenil ranked as the third most frequently administered antidote. In benzodiazepine toxicity during pregnancy, where supportive measures generally prove effective, a case report underscored flumazenil's potential to reverse fetal cardiac rhythm abnormalities induced by maternal diazepam overdose.<xref ref-type="bibr" rid="article-21842.r19">[19]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Exercise caution when considering flumazenil administration to breastfeeding women, as its presence in human milk is not established. Information on using flumazenil during breastfeeding is limited. If the mother requires flumazenil, breastfeeding can be continued. Given the drug's half-life of 54 minutes, abstaining from breastfeeding for 4 to 5 hours after administration can help minimize infant exposure.<xref ref-type="bibr" rid="article-21842.r20">[20]</xref></p>
        <p><bold>Pediatric patients: </bold>FDA&#x000a0;indicates use for benzodiazepine reversal in conscious sedation or general anesthesia.</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial dose of 0.01 mg/kg&#x000a0;administered over 15 seconds (up to a maximum&#x000a0;dosage of 0.2 mg)</p>
          </list-item>
          <list-item>
            <p>If the desired level of consciousness is not obtained after 45 seconds, repeat 0.01 mg/kg (up to 0.2 mg) at 1-minute intervals as needed, up to&#x000a0;4 additional doses.</p>
          </list-item>
          <list-item>
            <p>The maximum total cumulative dose of 1 or 0.05 mg/kg, whichever is lower</p>
          </list-item>
          <list-item>
            <p>The mean total dose of 0.65 mg was administered during the clinical trial (range: 0.08 to 1 mg)</p>
          </list-item>
        </list>
        <p><bold>Older&#x000a0;patients: </bold>Studies involving subjects aged over 65, including one study with participants over 80 years, indicate that while benzodiazepine doses for inducing sedation should be lowered, the standard&#x000a0;dosage&#x000a0;of flumazenil&#x000a0;is effective for reversal in older adults.<bold/></p>
      </sec>
      <sec id="article-21842.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Serious Adverse Events</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sedation</p>
          </list-item>
          <list-item>
            <p>Neurologic effects</p>
          </list-item>
          <list-item>
            <p>Seizure</p>
          </list-item>
          <list-item>
            <p>Arrhythmias<xref ref-type="bibr" rid="article-21842.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Common Adverse Events</bold>
</p>
        <p>
<bold>Cardiovascular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Chest pain</p>
          </list-item>
        </list>
        <p>
<bold>Neurologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Confusion</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Impaired cognition</p>
          </list-item>
          <list-item>
            <p>Opisthotonus</p>
          </list-item>
          <list-item>
            <p>Shivering</p>
          </list-item>
          <list-item>
            <p>Somnolence</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
        </list>
        <p>
<bold>Immunologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Injection site reaction</p>
          </list-item>
        </list>
        <p>
<bold>Ophthalmic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Defects of the visual field and diplopia</p>
          </list-item>
          <list-item>
            <p>Blurred vision</p>
          </list-item>
        </list>
        <p>
<bold>Otic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Transient hearing impairment</p>
          </list-item>
        </list>
        <p>
<bold>Dermatologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Injection site pain</p>
          </list-item>
        </list>
        <p>
<bold>Psychiatric</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Psychotic disorder</p>
          </list-item>
          <list-item>
            <p>Agitation</p>
          </list-item>
          <list-item>
            <p>Panic attack<xref ref-type="bibr" rid="article-21842.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Tricyclic antidepressants:</bold> Exercise caution with flumazenil in mixed drug overdosage, especially involving tricyclic antidepressants like amitriptyline, nortriptyline, clomipramine, and imipramine&#x02014;seizure risk increases. In severe cyclic antidepressant toxicity marked by dysrhythmia, anticholinergic signs, and cardiovascular collapse, avoid flumazenil. Provide supportive care until antidepressant toxicity symptoms subside.<xref ref-type="bibr" rid="article-21842.r23">[23]</xref></p>
        <p><bold>Vecuronium:</bold> Vials of flumazenil and vecuronium can resemble each other after&#x000a0;the differently colored caps&#x000a0;are removed. Both vials may be stored in procedural areas, increasing the risk of a mix-up.<xref ref-type="bibr" rid="article-21842.r24">[24]</xref></p>
      </sec>
      <sec id="article-21842.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p><bold>Contraindications</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to flumazenil or benzodiazepines</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Benzodiazepine&#x000a0;administration for life-threatening diseases such as control of intracranial pressure or status epilepticus</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Signs of tricyclic antidepressant overdose<xref ref-type="bibr" rid="article-21842.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Flumazenil provokes panic attacks in patients with a history of panic disorder.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Convulsions may occur in patients with a chronic dependency on benzodiazepines.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Flumazenil may precipitate convulsions or altered cerebral blood flow in patients with a head injury.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased risk of seizures exists in epileptic patients on benzodiazepine treatment for a prolonged period.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Caution is advised in patients with drug dependency or alcoholism due to increased frequency of benzodiazepine tolerance and dependence.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Do not use as primary treatment in patients with severe lung disease with respiratory depression secondary to benzodiazepines.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Signs of tricyclic antidepressant overdose or mixed overdoses should not be treated with flumazenil.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>According to American Heart Association (AHA) guidelines for cardiac arrest, flumazenil reverses the respiratory depression induced by benzodiazepine poisoning; however, its utilization is constrained by significant risks and contraindications.<xref ref-type="bibr" rid="article-21842.r25">[25]</xref><xref ref-type="bibr" rid="article-21842.r26">[26]</xref><xref ref-type="bibr" rid="article-21842.r27">[27]</xref><xref ref-type="bibr" rid="article-21842.r28">[28]</xref><xref ref-type="bibr" rid="article-21842.r27">[27]</xref><xref ref-type="bibr" rid="article-21842.r26">[26]</xref><xref ref-type="bibr" rid="article-21842.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>
<bold>US Box Warning</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Seizures: Benzodiazepine reversal has correlations with&#x000a0;seizures. Seizures may happen more frequently in patients on benzodiazepines for long-term sedation or in patients showing signs of severe tricyclic antidepressant overdose. The required dosage of flumazenil should be measured and prepared by the&#x000a0;clinicians to manage seizures. Flumazenil use requires caution in patients relying on a benzodiazepine for seizure control.<xref ref-type="bibr" rid="article-21842.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21842.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients should have monitoring for respiratory depression, benzodiazepine withdrawal, and other residual effects of benzodiazepines for at least 2 hours.<xref ref-type="bibr" rid="article-21842.r31">[31]</xref>&#x000a0;Seizures may occur secondary to flumazenil administration. Seizures induced by flumazenil may require larger doses of benzodiazepine.<xref ref-type="bibr" rid="article-21842.r27">[27]</xref>&#x000a0;Monitor the patient for the possible return of sedation, mostly in those who are tolerant of benzodiazepines or in the case of long-acting benzodiazepine overdose. Re-sedation may be treated in adults by administering flumazenil again until the&#x000a0;therapeutic effect is achieved.<xref ref-type="bibr" rid="article-21842.r32">[32]</xref></p>
      </sec>
      <sec id="article-21842.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Flumazenil has some associations with the precipitation of seizures in patients with benzodiazepine dependency with a history of seizures. However, flumazenil overdose is extremely rare.</p>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anxiety</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Agitation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased muscle tone</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyperesthesia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Seizures</p>
          </list-item>
        </list>
        <p>
<bold>Management</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No precise antidote for flumazenil toxicity is available.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In mild to severe toxicity, symptomatic and supportive treatment should be a consideration.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>An overdose of flumazenil in a patient who is not a chronic benzodiazepine user would not be expected. Chronic benzodiazepine users experience withdrawal with abrupt discontinuation of the drug.<xref ref-type="bibr" rid="article-21842.r33">[33]</xref><xref ref-type="bibr" rid="article-21842.r34">[34]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Consult Criteria</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Contact a medical toxicologist or local poison center for any patient with suspected severe adverse effects after receiving flumazenil, such as seizures, dysrhythmias, and hypotension.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Seizures after flumazenil administration&#x000a0;are significantly associated with exposure to a pro-convulsant drug.<xref ref-type="bibr" rid="article-21842.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21842.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Today, with the epidemic of drug overdoses, nurses, pharmacists, and&#x000a0;clinicians need to feel comfortable using flumazenil. This competitive antagonist of benzodiazepines can rapidly reverse benzodiazepine overdose. Despite the initial hype about the drug, many experts believe its risks may outweigh its benefits. The problem with flumazenil is that its effects are not consistent or predictable. The drug may precipitate seizures and withdrawal in patients using benzodiazepines for a medical disorder. Additionally, all clinicians&#x000a0;should be aware&#x000a0;that this drug should not be used in patients with a history of seizures, head injury, or those who have ingested a tricyclic antidepressant. The ideal circumstance for flumazenil is when a naive benzodiazepine individual has overdosed. The nurse and the pharmacist should educate the patient on the use of benzodiazepines and their potential to cause addiction and physical dependence.<xref ref-type="bibr" rid="article-21842.r36">[36]</xref><xref ref-type="bibr" rid="article-21842.r37">[37]</xref></p>
        <p>In general, patients who overdose on benzodiazepines alone rarely have significant mortality. The problem arises when the individual has co-ingested alcohol or other illicit drugs. In most isolated cases of benzodiazepine overdose, supportive management may prove useful. A few patients may develop rhabdomyolysis and aspiration pneumonia. Overall, the use of flumazenil to manage benzodiazepine overdose is diminishing as the drug may cause more harm than good.<xref ref-type="bibr" rid="article-21842.r1">[1]</xref><xref ref-type="bibr" rid="article-21842.r38">[38]</xref></p>
        <p>Normally, flumazenil overdose is handled by emergency department clinicians. Hospital pharmacists should&#x000a0;ensure proper dosing of flumazenil. Critical care consultation&#x000a0;is required in&#x000a0;severe poisoning with respiratory depression. In addition, medical toxicologist consultation is often required for multiple-drug ingestions. As depicted above, clinicians (MDs, DOs, NPs, and PAs) should collaborate to improve patient outcomes. An interprofessional team approach would help achieve maximum efficacy and minimize potential risks associated with flumazenil therapy.</p>
      </sec>
      <sec id="article-21842.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21842&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21842">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21842/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21842">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21842.s11">
        <title>References</title>
        <ref id="article-21842.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baandrup</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ebdrup</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>J&#x000d8;</given-names>
              </name>
              <name>
                <surname>Lindschou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Glenth&#x000f8;j</surname>
                <given-names>BY</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD011481</fpage>
            <pub-id pub-id-type="pmid">29543325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noviello</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hibbs</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Structure of a human synaptic GABA<sub>A</sub> receptor.</article-title>
            <source>Nature</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>559</volume>
            <issue>7712</issue>
            <fpage>67</fpage>
            <page-range>67-72</page-range>
            <pub-id pub-id-type="pmid">29950725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <article-title>Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: A Report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology.</article-title>
            <source>Anesthesiology</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>128</volume>
            <issue>3</issue>
            <fpage>437</fpage>
            <page-range>437-479</page-range>
            <pub-id pub-id-type="pmid">29334501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seelhammer</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>DeGraff</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Behrens</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Selleck</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Sprung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weingarten</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>[The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes].</article-title>
            <source>Braz J Anesthesiol</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>329</fpage>
            <page-range>329-335</page-range>
            <pub-id pub-id-type="pmid">29631877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Remimazolam-Flumazenil versus Propofol for Recovery from General Anesthesia: A Systematic Review and Meta-Analysis.</article-title>
            <source>J Clin Med</source>
            <year>2023</year>
            <month>Nov</month>
            <day>26</day>
            <volume>12</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">38068368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Alcohol withdrawal and flumazenil: not for the faint of heart.</article-title>
            <source>J Med Toxicol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-5</page-range>
            <pub-id pub-id-type="pmid">24595919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franchitto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pelissier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lauque</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lan&#x000e7;on</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series.</article-title>
            <source>Alcohol Alcohol</source>
            <year>2014</year>
            <season>Jan-Feb</season>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-83</page-range>
            <pub-id pub-id-type="pmid">24226812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asthana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic recurrent stupor mimicking status epilepticus.</article-title>
            <source>Singapore Med J</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>10</issue>
            <fpage>e276</fpage>
            <page-range>e276-7</page-range>
            <pub-id pub-id-type="pmid">18946597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crippa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Derenusson</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Chagas</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Atakan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Santos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zuardi</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Hallak</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature.</article-title>
            <source>Harm Reduct J</source>
            <year>2012</year>
            <month>Jan</month>
            <day>25</day>
            <volume>9</volume>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">22273390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reinert</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Burnham</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review.</article-title>
            <source>J Pharm Pract</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>922</fpage>
            <page-range>922-933</page-range>
            <pub-id pub-id-type="pmid">32878558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gottardo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chiamulera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bertoldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zamboni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lugoboni</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification.</article-title>
            <source>Front Psychiatry</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>646038</fpage>
            <pub-id pub-id-type="pmid">33815177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>An</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil in benzodiazepine overdose.</article-title>
            <source>CMAJ</source>
            <year>2016</year>
            <month>Dec</month>
            <day>06</day>
            <volume>188</volume>
            <issue>17-18</issue>
            <fpage>E537</fpage>
            <pub-id pub-id-type="pmid">27920113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amrein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hetzel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lorscheid</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacology of flumazenil.</article-title>
            <source>Eur J Anaesthesiol Suppl</source>
            <year>1988</year>
            <volume>2</volume>
            <fpage>65</fpage>
            <page-range>65-80</page-range>
            <pub-id pub-id-type="pmid">2842143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Rij</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Huitema</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Swart</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Greuter</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Lammertsma</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>van Loenen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Franssen</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>477</fpage>
            <page-range>477-85</page-range>
            <pub-id pub-id-type="pmid">16236037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiyama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Re-sedation after a large dose of flumazenil.</article-title>
            <source>J Anesth</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>161</fpage>
            <pub-id pub-id-type="pmid">36242628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parthvi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mehra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil for Mixed Drug Overdose.</article-title>
            <source>Am J Ther</source>
            <year>2018</year>
            <season>Nov/Dec</season>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>e676</fpage>
            <page-range>e676-e677</page-range>
            <pub-id pub-id-type="pmid">28708699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vilstrup</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amodio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cordoba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferenci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mullen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Weissenborn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.</article-title>
            <source>Hepatology</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>715</fpage>
            <page-range>715-35</page-range>
            <pub-id pub-id-type="pmid">25042402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janssen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>von Gaisberg</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil disposition and elimination in cirrhosis.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1989</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-23</page-range>
            <pub-id pub-id-type="pmid">2505960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zelner</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Matlow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hutson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wax</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Finkelstein</surname>
                <given-names>Y</given-names>
              </name>
              <collab>Toxicology Investigators Consortium (ToxIC)</collab>
            </person-group>
            <article-title>Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium.</article-title>
            <source>J Med Toxicol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-8</page-range>
            <pub-id pub-id-type="pmid">25783189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Flumazenil</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">37603673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penninga</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Graudal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ladekarl</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>J&#x000fc;rgens</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses of Randomised Trials.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>118</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-44</page-range>
            <pub-id pub-id-type="pmid">26096314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reversal Agents in Sedation and Anesthesia Practice for Dentistry.</article-title>
            <source>Anesth Prog</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-58</page-range>
            <pub-id pub-id-type="pmid">35377935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veiraiah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dyas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Routledge</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data.</article-title>
            <source>Emerg Med J</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>565</fpage>
            <page-range>565-9</page-range>
            <pub-id pub-id-type="pmid">21785147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grissinger</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paralyzed by Mistakes - Reassess the Safety of Neuromuscular Blockers in Your Facility.</article-title>
            <source>P T</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>91</fpage>
            <page-range>91-107</page-range>
            <pub-id pub-id-type="pmid">30828226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woolf</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cobaugh</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Booze</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Wax</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Manoguerra</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Scharman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Chyka</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Christianson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2007</year>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-33</page-range>
            <pub-id pub-id-type="pmid">17453872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seger</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil--treatment or toxin.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2004</year>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-16</page-range>
            <pub-id pub-id-type="pmid">15214628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haverkos</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>DiSalvo</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Imhoff</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Fatal seizures after flumazenil administration in a patient with mixed overdose.</article-title>
            <source>Ann Pharmacother</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>1347</fpage>
            <page-range>1347-9</page-range>
            <pub-id pub-id-type="pmid">7696723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sivilotti</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil, naloxone and the 'coma cocktail'.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>428</fpage>
            <page-range>428-36</page-range>
            <pub-id pub-id-type="pmid">26469689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Akpunonu</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Arens</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hoyte</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Mazer-Amirshahi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Stolbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>St-Onge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Drennan</surname>
                <given-names>IR</given-names>
              </name>
              <collab>American Heart Association</collab>
            </person-group>
            <article-title>2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</article-title>
            <source>Circulation</source>
            <year>2023</year>
            <month>Oct</month>
            <day>17</day>
            <volume>148</volume>
            <issue>16</issue>
            <fpage>e149</fpage>
            <page-range>e149-e184</page-range>
            <pub-id pub-id-type="pmid">37721023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spivey</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Flumazenil and seizures: analysis of 43 cases.</article-title>
            <source>Clin Ther</source>
            <year>1992</year>
            <season>Mar-Apr</season>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-305</page-range>
            <pub-id pub-id-type="pmid">1611650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rousseau-Blass</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cribb</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Beaudry</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (<italic>Oryctolagus cuniculus</italic>).</article-title>
            <source>J Am Assoc Lab Anim Sci</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>319</fpage>
            <page-range>319-328</page-range>
            <pub-id pub-id-type="pmid">33673881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maxa</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ogu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Adeeko</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Swaner</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity.</article-title>
            <source>Pharmacotherapy</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1513</fpage>
            <page-range>1513-6</page-range>
            <pub-id pub-id-type="pmid">14620397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallace</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Trimble</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Use of a flumazenil infusion to treat chlordiazepoxide toxicity.</article-title>
            <source>Acute Med</source>
            <year>2017</year>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-34</page-range>
            <pub-id pub-id-type="pmid">28424803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vukcevi&#x00107;</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Ercegovi&#x00107;</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Segrt</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Djordjevi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stosi&#x00107;</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine poisoning in elderly.</article-title>
            <source>Vojnosanit Pregl</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-8</page-range>
            <pub-id pub-id-type="pmid">27295906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreshak</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>A poison center's ten-year experience with flumazenil administration to acutely poisoned adults.</article-title>
            <source>J Emerg Med</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>677</fpage>
            <page-range>677-82</page-range>
            <pub-id pub-id-type="pmid">22766408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamburin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faccini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Casari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morbioli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Franchini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bongiovanni</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Lugoboni</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence.</article-title>
            <source>J Psychopharmacol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>1369</fpage>
            <page-range>1369-1373</page-range>
            <pub-id pub-id-type="pmid">28613124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tae</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Paradoxical reaction to midazolam in patients undergoing endoscopy under sedation: Incidence, risk factors and the effect of flumazenil.</article-title>
            <source>Dig Liver Dis</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>46</volume>
            <issue>8</issue>
            <fpage>710</fpage>
            <page-range>710-5</page-range>
            <pub-id pub-id-type="pmid">24893689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21842.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>O'Regan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sibbritt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Alprazolam is relatively more toxic than other benzodiazepines in overdose.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-95</page-range>
            <pub-id pub-id-type="pmid">15206998</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
